233
Participants
Start Date
November 9, 2016
Primary Completion Date
August 1, 2018
Study Completion Date
August 1, 2018
Benralizumab
Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
Placebo
Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
Research Site, Manila
Research Site, Gödöllő
Research Site, Balassagyarmat
Research Site, Komárom
Research Site, Miskolc
Research Site, Edelény
Research Site, Hajdúnánás
Research Site, Iloilo City
Research Site, Pécs
Research Site, Pécs
Research Site, Farkasgyepü
Research Site, Philadelphia
Research Site, Hamburg
Research Site, Hamburg
Research Site, New Bern
Research Site, Cheongju-si
Research Site, Hanover
Research Site, Hanover
Research Site, Winter Park
Research Site, Vero Beach
Research Site, Miami
Research Site, Tampa
Research Site, Scottsboro
Research Site, Fort Mitchell
Research Site, Daegu
Research Site, Cincinnati
Research Site, Jeonju
Research Site, Mainz
Research Site, Rochester
Research Site, Frankfurt am Main
Research Site, Frankfurt
Research Site, Frankfurt am Main
Research Site, Darmstadt
Research Site, Oklahoma City
Research Site, McKinney
Research Site, Lampasas
Research Site, Denver
Research Site, München
Research Site, Gilbert
Research Site, Bamberg
Research Site, Medford
Research Site, Santiago
Research Site, Curicó
Research Site, Santiago
Research Site, Santiago
Research Site, Hanover
Research Site, Lipa City
Research Site, Quezon City
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Lead Sponsor
AstraZeneca
INDUSTRY